MSB

3.21%

$1.13 mesoblast limited

only for a primary endpoint which is massively higher than the...

First 199 Last

Share
Profile

Follow
Praetorian2011

2,273 Posts.

374

26/01/21

23:34

Post #: 50455156
Share

Originally posted by Southoz: ↑

Well Praetorian2011 we are going to have to agree to disagree on this one.

In a traditional analysis you are comparing the mean response on a rating scale between two groups. Lets say pain – on a scale of 1-10 with 10 being worse pain.

So your treatment group scores on average 5 and your control group 8 at follow-up. Depending on your variability and sample size lets say this is a statistically significant result.

But now the question is whether this 3 point improvement is clinically significant. And you would turn to papers that have derived what is considered a minimum clinically important difference for the scale you have used and in this patient population.

In a responder analysis the problem of what to set as the MCID is just pushed one step down the track. What counts as a responder has been determined – the 50% improvement idea.

But what is being tested now is the proportion of responder in each group. What difference in proportions would be considered to be clinically significant – in the sense of would lead to a change in practice.

Any difference can be statistically significant with a large enough sample. And so its not like you can have 10,000 people and think that a 1% improvement is clinically significant.

Dig deep Praetorian2011 – where else can you get your sample size from – all roads eventually lead back to clinical significance; and statistical significance is set from this - not the other way around.

In terms of the question of whether there is a lot of headroom between the 37% response rate in the P2 trial and my estimate of what is required.

Yep – but this is a very unsophisticated way of looking at the question.

The difference between the 37% and control group estimate was not statistically significant – indicating wide confidence intervals. The estimates arose from a post-hoc analysis where the endpoint was created after the trial had completed. There were numerous methodological weaknesses in the P2 trial. The endpoint in the P3 back pain trial was changed midstream. The results are running late. The landscape is one where MSB has failed to produce a convincing P3 efficacy signal for anything after numerous attempts

That is case for the prosecution. It may still be a very good risk / reward play. That’s for everyone to do their own little assessment of.

Expand

only for a primary endpoint which is massively higher than the industry standard MCWTE for CLBP. If they miss this and nail it on a seconday it will still be a winner but I hope they wont based on the P2 data. Again they have gone high based on the P2 data so they didnt need 3000 people.

MSB Price at posting: $2.41 Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

There are more pages in this discussion • 75 more messages in this thread...

First 199 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

only for a primary endpoint which is massively higher than the...

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

only for a primary endpoint which is massively higher than the...

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News